Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: A retrospective study on various cytogenetic risk categories

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2410-2419

  Fiegl, M ^a   Erdel, M ^b   Tinhofer, I ^c   Brychtova, Y ^d   Panovska, A ^d   Doubek, M ^d   Eigenberger, K ^e   Fonatsch, C ^e   Hopfinger, G ^e   Muhlberger H ^e   Zabernigg, A ^e   Falkner, F ^a   Gastl, G ^a   Mayer, J ^d   Greil, R ^c  

^a Division of Hematology   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

^d MASARYK UNIVERSITY   (Czech Republic)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Cytogenetic abnormalities; FISH

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRALGIA; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BILE DUCT DISEASE; BRADYCARDIA; CANCER SURVIVAL; CHILL; CHOLECYSTITIS; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DYSPNEA; ENTEROCOLITIS; FEMALE; FLUSHING; GENETIC RISK; HEART FAILURE; HEMOLYSIS; HERPES SIMPLEX; HUMAN; HYPOTENSION; LUNG ASPERGILLOSIS; LUNG EMBOLISM; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; OTITIS; OVERALL SURVIVAL; PERICARDITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY; SEPTICEMIA; SIDE EFFECT; SKIN CARCINOMA; STOMACH PAIN; STOMATITIS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TONSILLITIS; TREATMENT DURATION; TREATMENT RESPONSE; TRISOMY; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT CANCER; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; DRUG TOXICITY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78649471912     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq236     Document Type: Article

References (36)

1. Kay NE, O'Brien SM, Pettitt AR et al. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007; 21: 1885-1891.
2. Dö hner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-143.
4. Riechmann L, Clark M, Waldmann H et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
5. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
6. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979.
7. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574.
8. Rai K, Keating MJ, Coutre S et al. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM511 trial. Blood 2002: 100: 802a (Abstr 3165).
9. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-3897.
10. Sayala HM, Moreton P, Jones RA et al. Final report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL. Blood 2006: 108: 14a (Abstr 34[0]).
11. Ferrajoli A, O'Brien SM, Cortes JE et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773-778.
12. Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
13. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
14. Fiegl M, Falkner A, Hopfinger G et al. Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408-2416.
15. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
16. Stilgenbauer S, Zenz T, Winkler D et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
17. Pettit AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441-1445.
18. Osuji NC, Del Giudice I, Matutes E et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90: 1435-1436.
19. Cortelezzi A, Pasquini MC, Sarina B et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. Haematologica 2005; 90: 410-412.
20. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634-4641.
21. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7: 125-130.
22. Keating M, Coutre S, Rai K et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4: 220-227.
23. Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
24. Wierda WG, O'Brien S, Faderl S et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 2006; 108: 14a (Abstr 31).
25. Dickinson JD, Gilmore J, Iqbal J et al. 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006; 47: 231-244.
26. Hui D, Lam W, Toze C et al. Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 2008; 49: 218-226.
27. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
28. Rieger K, Von Grü nhagen U, Fietz T et al. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia-change of regimen needed? Leuk Lymphoma 2004; 45: 345-349.
29. Cortelezzi A, Pasquini MC, Gardellini A et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009; 23: 2027-2033.
30. Robak T, Moiseev SI, Dmoszynska A et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the International Randomized Phase III REACH Trial. Blood 2008: 112 (late-breaking Abstr 1).
31. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008; 112: 128 (Abstr 330).
32. Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404.
33. Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343-5349.
34. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009; 1: 602-609.
35. Haferlach C, Dicker F, Schnittger S et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442-2451.
36. Fiegl M, Falkner F, Falkner A et al. Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL. Blood 2007; 110: 252b (Abstr 4714).